Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI

Next Previous
Search
Trial Profile

Randomized Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Cancer metastases; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms BEV-ONCO; BEV-ONCO2012

Most Recent Events

  • 21 Sep 2020 Primary endpoint (the major pathological response rate) has not been met as per results presented at the 45th European Society for Medical Oncology Congress
  • 21 Sep 2020 Status changed from recruiting to completed as per results presented at the 45th European Society for Medical Oncology Congress .
  • 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top